Immunitybio, Inc.
Clinical trials sponsored by Immunitybio, Inc., explained in plain language.
-
Experimental cell therapy takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new treatment using a person's own immune cells, called M-CENK, combined with a booster drug (N-803) for advanced solid tumors that have spread. About 50 adults with either newly diagnosed or previously treated cancers will receive the therapy to se…
Phase: PHASE1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New immunotherapy cocktail takes on tough pancreatic cancer
Disease control OngoingThis study tests whether adding a combination of immunotherapy drugs (aldoxorubicin, N-803, and PD-L1 t-haNK) to standard chemotherapy can help people with advanced pancreatic cancer live longer without their disease getting worse. About 328 adults with locally advanced or metast…
Phase: PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
Bladder cancer trial combines two drugs to boost immune attack
Disease control OngoingThis study tests whether adding a drug called N-803 to standard BCG therapy works better than BCG alone for people with a type of bladder cancer that hasn't spread into the muscle. About 369 participants will receive either the combination or BCG alone. The goal is to see if the …
Phase: PHASE1, PHASE2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC